Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.49 |
| ▸ | GRM5 | P41594 | 7/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | EED | O75530 | 3/20 | 0.45 |
| ▸ | RBBP4 | Q09028 | 3/20 | 0.45 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245699 | 1.00 | PDK4 (0.50) | PDK4GRM1GRM5BTKCDK9 | |
| SCHEMBL1804728 | 0.88 | PDK4 (0.51) | PDK4GRM1GRM5BTKCYP11B2 | |
| SCHEMBL30439316 | 0.88 | PDK4 (0.51) | PDK4GRM1GRM5BTKCYP11B2 | |
| SCHEMBL30439968 | 0.86 | GRM1 (0.50) | PDK4GRM1GRM5BTKCYP11B2 | |
| SCHEMBL21045699 | 0.86 | GRM1 (0.50) | PDK4GRM1GRM5BTKCYP11B2 | |
| SCHEMBL21045851 | 0.83 | JAK1 (0.49) | PDK4GRM1GRM5BTKCDK9 | |
| SCHEMBL29774097 | 0.83 | JAK1 (0.49) | PDK4GRM1GRM5BTKCDK9 | |
| SCHEMBL29197065 | 0.83 | PDK4 (0.53) | PDK4GRM1GRM5CDK9JAK1 | |
| SCHEMBL29744751 | 0.82 | PDK4 (0.54) | PDK4GRM1GRM5BTKCDK9 | |
| SCHEMBL6402391 | 0.82 | PDK4 (0.54) | PDK4GRM1GRM5BTKCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | PDK4 153/4885GRM1 2912/4885GRM5 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.